Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × OTHER × Inflammation × Clear all

Phase

Phase NA 66 Phase 2 15 Phase 4 13 Phase 1 7 Phase 1/2 3 Phase EARLY_PHASE1 2 Phase 3 2 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 91 Neoplasms 75 Prostatic Neoplasms 53 Carcinoma, Hepatocellular 53 Colorectal Neoplasms 48 Leukemia, Myeloid, Acute 40 Stomach Neoplasms 35 Carcinoma, Non-Small-Cell Lung 35 Precursor Cell Lymphoblastic Leukemia-Lymphoma 34 Neoplasm Metastasis 29 Pancreatic Neoplasms 27 Lung Neoplasms 26 Rectal Neoplasms 23 Multiple Myeloma 21 Hematologic Neoplasms 21 Colonic Neoplasms 20 Recurrence 19 Lymphoma 19 Leukemia 19 Head and Neck Neoplasms 19 Polycystic Ovary Syndrome 15 Liver Neoplasms 14 Esophageal Neoplasms 14 Myelodysplastic Syndromes 12 Endometrial Neoplasms 12 Brain Neoplasms 12 Uterine Cervical Neoplasms 11 Motor Activity 11 Melanoma 11 Fatigue 11

Interventions

Dexmedetomidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04106999 2022-11-03

Dexmedetomidine and HIPEC

University of British Columbia

Phase 2/3 Unknown

Inflammation, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡